Magi Astrology--Financial Astrology

FINANCIAL ASTROLOGY

First Trade Date for Cephalon Inc.

Company Name	First Trade Date (yyyy-mm-dd)
Cephalon Inc.	1991-04-25

Company Name	Symbol
Cephalon Inc.	CEPH
History and Business of Company (this information may include date of incorporation)
Cephalon Inc. (CEPH) is an international biopharmaceutical company engaged in the discovery, development and marketing of products to treat neurological disorders, sleep disorders, cancer and pain. The company provides patients and the medical community with pharmaceuticals to treat unmet medical conditions through its research programs and through acquisition of promising products for clinical development and commercial sale. CEPH markets three products in the U.S.: PROVIGIL, to treat excessive daytime sleepiness associated with narcolepsy; ACTIQ, to manage breakthrough cancer pain in opioid tolerant patients; and GABITRIL, used to treat partial seizures associated with epilepsy. In the United Kingdom, the company markets PROVIGIL and five additional products, including the epilepsy treatment Tegretol, and Ritalin for the treatment of attention deficit hyperactivity disorder. Additional products are marketed in France, Germany, Austria and Switzerland. The company's research and development program is focused on expanding the use of its three core products- PROVIGIL, ACTIQ and GABITRIL. CEPH has an ongoing clinical study to explore PROVIGIL's use in treating excessive daytime sleepiness or fatigue, and is also conducting clinical studies on the use of PROVIGIL to treat disorders other than narcolepsy. PROVIGIL is the first wake- promoting agent approved by the U.S. Food and Drug Administration (FDA). In October 2000, CEPH acquired the worldwide product rights to ACTIQ through its acquisition of Anesta Corp. in a stock transaction. ACTIQ is administered through CEPH's oral transmucosal delivery system which delivers Fentanyl citrate, an opioid analgesic. In January 2001, the company acquired the U.S. rights to market GABITRIL (tiagabine hydrochloride), an adjunctive treatment for partial seizures associated with epilepsy, from Abbott Laboratories. In 2000, PROVIGIL, ACTIQ and GABITRIL accounted for 97% of product revenues. Cephalon is also collaborating with H. Lundbeck A/S to develop orally-active, small molecules for the treatment of neurodegenerative diseases, one of which, CEP-1347, will enter Phase II clinical studies. The company is also collaborating on the development of compounds to treat prostate, pancreatic and other cancers, one of which, CEP-701, is in Phase II clinical studies. CEPH has a collaboration with Chiron Corp. for the development and commercialization of Myotrophin and certain other technologies in the neurological field in the U.S., Canada and Europe. CEPH is developing Myotrophin to treat ALS. INCORPORATED in Delaware August 24, 1987. OFFICE- 145 Brandywine Pkwy., West Chester, PA 19380-4245 (Tel.: 610-344-0200). Fax - 610-344-0065. WEBSITE-http://www.cephalon.com.

IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.